OMDAOmada Health, Inc.
Is the price fair?
Priced for a lot of growth. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~18% a year FCF growth. The price already bakes in strong, sustained growth.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What OMDA's price assumes
Omada Health, Inc. has no trailing P/E on file, so the price is measured against sales instead: 4.32× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 2.0%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- +18%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 4.89
Price / book · today's price, fiscal year to Dec 31, 2025
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 4.89
- EV / EBIToperating margin −0.15%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 3.46
- Free cash flow, trailing twelve months
- $23M
- Market capitalisation
- $1.12B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
The closest names by size in the same industry